Novel immunotherapy approaches for small cell lung cancer

Renal cell cancer: Highlights from ASCO 2020

HERO: Relugolix versus leuprolide acetate for advanced prostate cancer

MASTER trial updates: Dara-KRd induction, autologous transplantation and MRD response-adapted consolidation in NDMM

UKALL2011: Treatment with a tyrosine kinase inhibitor improves outcomes for patients with acute lymphoblastic leukaemia and an ABL-class fusion

Phase I/II results: First-line NALIRIFOX in patients with pancreatic ductal adenocarcinoma

Long-term disease control in multiple myeloma by in-class transitioning: A community-based study

Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma

The future of PARP inhibitors in prostate cancer

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC

Treating patients with multiple myeloma in the real world